ATHLONE, Ireland -- Innocoll AG (Nasdaq:INNL) today announced that James Tursi, M.D., has been appointed chief medical officer. Dr. Tursi will be responsible for managing all clinical development programs and medical affairs for the company.
"James is a great addition to the Innocoll team and is joining the company at a very exciting time as we advance our lead products through late stage clinical testing," said Tony Zook, chief executive officer of Innocoll. "His experience and background add significant depth and expertise to our clinical development function. James' joining Innocoll is further evidence of our progress at the company since our IPO last summer."
Dr. Tursi has extensive experience developing pharmaceuticals across a number of therapeutic areas. Most recently, as vice president of Research & Development and chief medical officer at Auxilium, he oversaw the development and regulatory approval of Xiaflex® in the U.S. and in global markets for two indications as well as moving four additional indications into advanced clinical development. Prior to his tenure at Auxilium, Dr. Tursi was responsible for medical affairs for cervical cancer vaccines in North America for GlaxoSmithKline. Dr. Tursi was also previously medical director for Proctor & Gamble Pharmaceuticals where he managed development of products in female sexual dysfunction, overactive bladder, and osteoporosis.
"Innocoll is at a transformative time in its history with three late-stage candidates and with a drug development engine based on its proprietary collagen drug formulation platform," said Dr. Tursi. "I am looking forward to working with the team to move our current assets toward the market and to developing new drug candidates that have the promise of improving patient care."
About Innocoll AG
Innocoll is a global, commercial-stage, specialty pharmaceutical company. The company develops and manufactures a range of pharmaceutical products and medical devices using its proprietary collagen-based technologies. The company's late-stage product pipeline is focused on addressing a number of large unmet medical needs, including: XaraColl® for the treatment of post-operative pain; Cogenzia® for the adjuvant treatment of diabetic foot infections; and CollaGUARD®, a barrier for the prevention of post-surgical adhesions. The Company's approved products include: CollaGUARD, Collatamp® G, Septocoll®, RegenePro®, Collieva®, CollaCare®, Collexa®, and Zorpreva™, which are sold through strategic partnerships with various partners including Takeda, Biomet, and Jazz Pharmaceuticals.
CollaRx®, Collatamp®, CollaGUARD®, Collieva®, CollaCare®, Collexa®, Cogenzia® LidoColl®, LiquiColl®, and XaraColl® are registered trademarks, and CollaPress™, DermaSil™, Durieva™, and Zorpreva™ are trademarks of the company.